

Miriam Molina-Arcas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6308442/publications.pdf>

Version: 2024-02-01

31
papers

2,685
citations

279798

23
h-index

434195

31
g-index

33
all docs

33
docs citations

33
times ranked

5385
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Oncogenic RAS Signaling Promotes Tumor Immuno-resistance by Stabilizing PD-L1 mRNA. <i>Immunity</i> , 2017, 47, 1083-1099.e6. | 14.3 | 450 |
| 2 | The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer. <i>Cell</i> , 2012, 149, 642-655. | 28.9 | 247 |
| 3 | Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. <i>Lancet</i> , The, 2020, 396, e6-e7. | 13.7 | 196 |
| 4 | Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. <i>Cell Research</i> , 2012, 22, 1227-1245. | 12.0 | 155 |
| 5 | Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2013, 3, 548-563. | 9.4 | 153 |
| 6 | Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. <i>Science Translational Medicine</i> , 2019, 11, . | 12.4 | 150 |
| 7 | Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. <i>Clinical Cancer Research</i> , 2003, 9, 5000-8. | 7.0 | 144 |
| 8 | Nucleoside Transporter Proteins. <i>Current Vascular Pharmacology</i> , 2009, 7, 426-434. | 1.7 | 135 |
| 9 | Cell entry and export of nucleoside analogues. <i>Virus Research</i> , 2005, 107, 151-164. | 2.2 | 127 |
| 10 | Transport of Lamivudine [(-)-2',3'-Dideoxy-3-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 252-261. | 2.5 | 125 |
| 11 | RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. <i>Cancer Cell</i> , 2019, 36, 68-83.e9. | 16.8 | 104 |
| 12 | Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2003, 101, 2328-2334. | 1.4 | 101 |
| 13 | Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 558-567. | 2.5 | 66 |
| 14 | SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. <i>Nature Communications</i> , 2019, 10, 2532. | 12.8 | 53 |
| 15 | RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression. <i>Nature Communications</i> , 2016, 7, 11245. | 12.8 | 52 |
| 16 | Drugging the Undruggable: Advances on RAS Targeting in Cancer. <i>Genes</i> , 2021, 12, 899. | 2.4 | 44 |
| 17 | A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter hCNT3 protein localized in the endoplasmic reticulum. <i>FASEB Journal</i> , 2009, 23, 172-182. | 0.5 | 42 |
| 18 | IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche. <i>Nature Communications</i> , 2020, 11, 764. | 12.8 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Physiological and Pharmacological Roles of Nucleoside Transporter Proteins. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2008, 27, 769-778. | 1.1 | 40 |
| 20 | Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. <i>Nature Communications</i> , 2021, 12, 5906. | 12.8 | 36 |
| 21 | Scalable and robust SARS-CoV-2 testing in an academic center. <i>Nature Biotechnology</i> , 2020, 38, 927-931. | 17.5 | 32 |
| 22 | Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs. <i>BMC Cancer</i> , 2012, 12, 434. | 2.6 | 28 |
| 23 | Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5-DFUR in breast cancer MCF7 cells. <i>Biochemical Pharmacology</i> , 2006, 72, 1646-1656. | 4.4 | 27 |
| 24 | Hypoxia and P1 receptor activation regulate the high-affinity concentrative adenosine transporter CNT2 in differentiated neuronal PC12 cells. <i>Biochemical Journal</i> , 2013, 454, 437-445. | 3.7 | 26 |
| 25 | Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells. <i>Biochemical Pharmacology</i> , 2008, 75, 639-648. | 4.4 | 23 |
| 26 | Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2008, 93, 1843-1851. | 3.5 | 20 |
| 27 | The Human Concentrative Nucleoside Transporter-3 C602R Variant Shows Impaired Sorting to Lipid Rafts and Altered Specificity for Nucleoside-Derived Drugs. <i>Molecular Pharmacology</i> , 2010, 78, 157-165. | 2.3 | 19 |
| 28 | Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. <i>Science Translational Medicine</i> , 2021, 13, . | 12.4 | 19 |
| 29 | Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. <i>Epilepsy and Behavior</i> , 2021, 115, 107602. | 1.7 | 11 |
| 30 | 3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes. <i>Antiviral Therapy</i> , 2006, 11, 803-11. | 1.0 | 7 |
| 31 | How to Fool a Wonder Drug: Truncate and Dimerize. <i>Cancer Cell</i> , 2012, 21, 7-9. | 16.8 | 5 |